Apyx Medical Corp

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apyx Medical Corp reports Q4 revenue decline, eyes 2023 growth

Apyx Medical Corp faced revenue challenges in Q4 2022, but secured new clearances and credit facilities.
The company anticipates improved revenue and profitability in 2023 with strategic initiatives.
Despite losses and reduced cash reserves, Apyx aims to enhance product offerings and financial stability.
Management's actions aim to address concerns and position the company for growth in 2023.

Apyx Medical Corp reports Q1 revenue beat but faces cost challenges

Apyx Medical Corp faced mixed results in Q1 2023 with revenue exceeding expectations but a decline in gross profit and net loss.
The company showcased strengths in OEM sales, product launches, and property transactions, while grappling with challenges in certain sales segments.
With revised revenue guidance, margin expectations, and growth opportunities, Apyx has a strategic roadmap for future performance improvements.

Apyx Medical Corp reports strong Q2 growth and reaffirms 2023 guidance

Apyx Medical Corp demonstrated robust growth in Q2 2023, driven by Advanced Energy product sales and operational efficiency improvements.
While facing challenges in certain regions and managing operating expenses, the company's strategic initiatives and revenue diversification are key strengths.
With reaffirmed financial guidance and opportunities for market expansion, Apyx is poised for continued growth and innovation in the medical device industry.

Apyx Medical Corp reports robust Q3 performance and strategic initiatives

Apyx Medical Corp's Q3 2023 earnings call showcased strong revenue growth, improved gross profit margins, and strategic initiatives to address challenges. With a focus on operational efficiency and new product introductions, the company aims to drive future growth and profitability.

Apyx Medical Corp reports strong Q4 revenue growth and eyes market expansion

Apyx Medical Corp delivered strong revenue growth in Q4 2023 driven by Advanced Energy products and international sales performance.
While facing challenges in net loss and operating expenses, the company's technology and clinical support remain key strengths.
Opportunities lie in financial growth targets, market recognition, and leveraging positive feedback to drive future success.
Overall, Apyx Medical Corp's performance reflects resilience and potential for growth in the medical technology sector.

Apyx Medical Corp reports Q1 revenue decline, focuses on cost control

Apyx Medical Corp faced revenue decline in Q1 2024, driven by lower Advanced Energy sales.
The company showcased strengths in cost control, operational achievements, and revenue diversification.
Challenges include declining Advanced Energy sales and a projected net loss for 2024.
Opportunities lie in driving Renuvion technology adoption and addressing segment sales challenges.

Apyx Medical Corp reports Q3 revenue decline, bets on Ayon

Apyx Medical Corp's Q3 2024 performance reflects a mixed financial picture with revenue decline but promising growth in key segments like disposable handpieces.
Management's strategic initiatives, including the Ayon system launch and cost-saving measures, aim to drive future growth and achieve cash flow breakeven by 2027.
While facing revenue challenges and financial losses, the company's focus on operational efficiency and product innovation presents opportunities for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, May 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading...

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Apyx Medical Corporation - APYX

Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Apyx (APYX) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor of Apyx Medical

Will Apyx Medical Continue to Surge Higher?

Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q1 2020 Results - Earnings Call Transcript

Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates

Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.

Apyx Medical: Q1 Earnings Insights

Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2019 Results - Earnings Call Transcript

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Apyx (APYX) Upgraded to Strong Buy: Here's Why

Applied Materials

Ascendis Pharma

Top Ranked Momentum Stocks to Buy for November 21st

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2019 Results - Earnings Call Transcript

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Apyx (APYX) a New Buy Stock

Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q2 2019 Results - Earnings Call Transcript

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Apyx Medical (APYX) Q2 Earnings Expected to Decline

Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2019 Results - Earnings Call Transcript

Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.

News for Apyx Medical Corp Stock (APYX)